The aberrant pathways currently under investigation include the following: Wnt/β-catenin signalling (activated in up to 50% of HCC) [70]; phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/Mtor) (activated in 40–60% of HCC) [71]; Myc (activated in 30–60% of HCC) [72,73]; Hedgehog signalling (activated in 50–60% of HCC) [74,75]; and mesenchymal epithelial transition (MET) (activated in 30–40% of HCC) responsible for metastasis and migration [76]. Here, MYC is linked to hepatocellular carcinoma.